Compounded Tirzepatide Cost: What You'll Really Pay in 2026

By The RX Index Editorial Team · Last verified October 2026

Compounded tirzepatide cost runs about $99 to $199 a month all-in at the starting prices of the five online providers we checked on October 29, 2026. The headline price is rarely the whole bill, though. Prepaid plans, separate membership fees and dose-based pricing can change your yearly total by hundreds of dollars. It's cash only and not FDA-approved.

Below, we turn each provider's advertised price into what you'd actually pay over a year, show the refund and cancellation rules that come with the cheapest plans, and explain when FDA-approved Zepbound is worth the extra cost.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Decision Verdict

Compounded tirzepatide is the lowest-cost way to get tirzepatide without insurance, but the cheapest-looking price usually comes with a long prepaid commitment or a separate membership fee. Compare the 12-month total and the refund rules, not the banner price.

• Best for: Adults paying cash who have no coverage for Zepbound or Mounjaro, who are comfortable with a medicine that isn't FDA-approved, and who will stay on treatment long enough to benefit from a longer plan's lower price.
• Not ideal for: Anyone whose insurance covers Zepbound or Mounjaro, anyone who wants only FDA-approved medicine, and anyone unsure they'll stay on treatment, since the lowest prices usually require prepaying for months with no refund for unused time.
• The factor that matters most: What's included. Some prices include the medication, visits and shipping at every dose. Others cover the medication only, and a membership fee is added on top.

How much does compounded tirzepatide cost per month?

Here's what each provider listed on its own site on October 29, 2026. "All-in monthly" is the lowest monthly amount that covers both the medication and any required membership.

Two prices come with a catch. Mochi's $90 and Alloy's $100 are starting prices, so if your prescriber moves you to a higher dose, your bill can go up. Mochi lists its medication at $90 for the lowest weekly dose up to $199 for the highest, before the membership fee, and its page doesn't say how long each price covers. MEDVi's tirzepatide page shows $166 at the top and $199 in its FAQ, so confirm the number at checkout before you pay.

What a year of compounded tirzepatide costs

Monthly prices hide the real difference between plans. Here's the 12-month total at each provider's starting price.

The spread is about $1,200 a year between the cheapest and most expensive way to buy compounded tirzepatide. Plan length alone moves Embody's yearly cost by $360 and Gimme's by $600.

These are our calculations from each provider's posted prices. They don't include lab work, state taxes or any price change after you start.

Not sure whether compounded tirzepatide or an FDA-approved option is the better fit for your budget and coverage? The RX Index's Find My GLP-1 Path tool. It's free, takes about 2 minutes, and needs no signup: you answer a few quick questions and get the GLP-1 paths and providers that fit your goals, budget, insurance and situation, with verified pricing and the right questions to ask.

Why is the advertised price different from what you pay?

Four things usually separate the banner price from your real bill:

1. The lowest price needs a long plan. Embody's $99 is its 12-month price, billed as $1,188 upfront. Its month-to-month price is $129. Gimme's $149 needs a 6-month supply.
2. Membership fees are separate at some providers. Mochi's medication price doesn't include its membership, and Alloy charges a $99 monthly care fee on top of the medication.
3. Some prices change with your dose. Mochi says the price varies with the dose your provider prescribes. Embody and Gimme say their price covers every dose.
4. Sale prices end. Embody's site was running a "Pre-Black Friday Sale" on October 29, showing $129 against a regular price of $349 for its monthly tirzepatide plan. Embody's terms list $129 as the monthly price, but sale banners can change.

What are the refund and cancellation rules?

This is where a cheap plan can turn expensive. If you stop early, a prepaid plan may not give any money back.

Embody's terms, for example, say that if you pick a 3-, 6- or 12-month plan, you agree to the full commitment period, and refunds aren't issued for unused months unless a provider medically disqualifies you. Cancellations have to reach Embody at least 72 hours before your next billing date, or the next charge goes through and can't be refunded. Its terms also say the final charge may vary based on the prescribed medication and the pharmacy that fills it.

Before you prepay anywhere, ask:

• "If I stop after two months, do I get anything back?"
• "Does the price change if my dose goes up?"
• "Is the membership or care fee included, or billed separately?"
• "How much notice do you need to cancel before the next charge?"
• "Which pharmacy compounds my medication, and is it licensed in my state?"

Is compounded tirzepatide cheaper than Zepbound?

Yes, usually by a lot. Lilly's Zepbound vial costs $299 a fill at the 2.5 mg starting strength through LillyDirect, according to TrumpRx, and higher strengths cost more. That's roughly double the all-in price of the cheaper compounded plans.

What you get for the extra money: Zepbound is FDA-approved, so its safety, effectiveness and manufacturing quality have been reviewed by the FDA. Compounded tirzepatide hasn't gone through that review. See the LillyDirect Zepbound vial price vs insurance and compounded vs name-brand GLP-1s. For every lower-cost route, including brand-name vials, see the cheapest tirzepatide online without insurance.

If your insurance covers Zepbound or Mounjaro, your copay may beat any cash price. That's worth checking before you pay cash for anything.

Is compounded tirzepatide still legal in 2026?

Compounding pharmacies can still make tirzepatide for an individual patient with a prescription, under rules the FDA restated on April 1, 2026. That FDA statement also says:

• Tirzepatide isn't on the FDA's drug shortage list or on the 503B bulks list, which is the list outsourcing facilities need to compound from bulk ingredients.
• A compounded product that is essentially a copy of an approved drug can't be made regularly or in large amounts, unless the prescriber documents a significant difference for that patient.

On May 1, 2026, the FDA proposed keeping tirzepatide, semaglutide and liraglutide off the 503B bulks list. The public comment period closed July 30, 2026. As of October 29, 2026, we haven't found a final decision. A final rule could affect which pharmacies can make it and what it costs, which is one more reason to think twice before prepaying a year in advance.

For background, see the 503B bulks list explained, whether compounded GLP-1s are still available and compounded GLP-1 laws by state.

How to spot a compounded tirzepatide price that's too good to be true

The FDA warns that prices that seem too good to be true are a red flag, along with any claim that a compounded drug is identical to an FDA-approved one. It also reports fraudulent compounded tirzepatide with labels naming pharmacies that didn't make the product, and products falsely sold "for research purposes."

The FDA says that as of May 31, 2026, it had received more than 730 adverse event reports tied to compounded tirzepatide, and says the true number is likely higher because federal law doesn't require state-licensed pharmacies that aren't outsourcing facilities to report them.

A legitimate offer includes a visit with a licensed prescriber, a prescription in your name, and a named, state-licensed pharmacy. A vial sold without a prescription, or labeled "not for human consumption," isn't a safe way to save money.

Can you use insurance or an HSA for compounded tirzepatide?

Insurance almost never pays for it. The providers we checked are cash pay, and Embody's terms say its affiliated medical providers aren't contracted with any health insurance plan, including Medicare and Medicaid. Medicare's GLP-1 Bridge covers Zepbound KwikPen, Wegovy and Foundayo for eligible people, not compounded tirzepatide or Zepbound vials.

HSA and FSA cards are often accepted. Embody advertises "HSA/FSA Approved," but whether your plan treats a compounded drug as an eligible expense depends on your plan rules. See whether compounded tirzepatide is HSA or FSA eligible.

Which compounded tirzepatide plan fits you

Not sure which row is yours? Find My GLP-1 Path sorts it out in about 2 minutes.

What we actually verified

• Opened Embody's terms, product listing and homepage, and recorded its tirzepatide prices, plan lengths, refund and cancellation rules.
• Opened the compounded tirzepatide pages for Gimme Care, Mochi Health, Alloy and MEDVi, and recorded each price and what it includes. We also opened Mochi's homepage for its membership fees.
• Read the TrumpRx Zepbound vial page for the 2.5 mg price.
• Read the FDA's April 1, 2026 compounding statement, its page on concerns with unapproved GLP-1 drugs (current as of October 1, 2026), and the Federal Register notice on the 503B bulks list proposal.
• Read Medicare.gov's GLP-1 Bridge page.
• Did the yearly math ourselves from each provider's posted prices.

What we did not do: sign up with or buy from any provider, see a price after a medical intake, confirm dose-by-dose prices at Alloy or what each Mochi dose price covers, test cancellations or refunds, or check any specific pharmacy's license or quality. Prices and offers change, so confirm them at checkout before you pay.

Frequently asked questions

How much is compounded tirzepatide per month?

At the five online providers we checked, compounded tirzepatide costs about $99 to $199 a month all-in at starting prices. The lowest prices need a long plan, like Embody's $99 on a prepaid 12-month plan. Month-to-month prices run about $129 to $199, and some providers add a membership fee or charge more at higher doses.

Why is compounded tirzepatide so much cheaper than Zepbound?

Compounded tirzepatide is made by compounding pharmacies for individual prescriptions and doesn't go through the FDA approval process that Zepbound did. That's also its main drawback: the FDA hasn't evaluated compounded versions for safety, effectiveness or quality. Zepbound vials start at $299 a fill at the 2.5 mg strength.

Does the price of compounded tirzepatide go up with the dose?

It depends on the provider. Embody says its price includes all doses, and Gimme Care says its price is the same at every dose. Mochi Health says its price varies with the dose your provider prescribes and lists $90 to $199 across its doses, plus the membership. Alloy lists a starting price. Ask before you sign up if you expect your dose to increase.

What's the cheapest way to get compounded tirzepatide?

Among the providers we checked, Embody's 12-month plan was the lowest total at $1,188 a year, which works out to $99 a month. You pay it upfront, though, and unused months aren't refunded. If you aren't sure you'll stay on treatment, a slightly higher monthly price may cost less overall.

Is there a membership fee for compounded tirzepatide?

Some providers charge one. Mochi Health requires a membership of $79 a month, or $49 a month on a 12-month plan, plus the medication. Alloy charges a $99 monthly care fee on top of the medication. Embody, Gimme Care and MEDVi say they don't charge a separate membership fee.

Will compounded tirzepatide prices change in 2026?

They could. The FDA proposed in May 2026 to keep tirzepatide off the 503B bulks list, and as of October 29, 2026, we haven't found a final decision. Providers also run sales that end, so the price you see today isn't guaranteed later unless your provider promises a locked rate in writing.

Is compounded tirzepatide safe?

It isn't FDA-approved, so the FDA hasn't reviewed it for safety, effectiveness or quality. The FDA has received more than 730 adverse event reports tied to compounded tirzepatide and warns about fake and mislabeled products. Use a licensed prescriber and a state-licensed pharmacy, and talk with your clinician about the risks.

Sources

• Embody: terms and conditions (last updated April 24, 2026), product listing, homepage (checked October 29, 2026)
• Gimme Care: compounded tirzepatide (checked October 29, 2026)
• Mochi Health: compounded tirzepatide, membership pricing (checked October 29, 2026)
• Alloy: compounded tirzepatide (checked October 29, 2026)
• MEDVi: tirzepatide (checked October 29, 2026)
• TrumpRx: Zepbound vial (checked October 29, 2026)
• FDA: policies for compounders as GLP-1 supply stabilizes (April 1, 2026), concerns with unapproved GLP-1 drugs (current as of October 1, 2026)
• Federal Register: 503B bulks list comment period extension (June 26, 2026)
• Medicare.gov: weight-loss drugs and the GLP-1 Bridge (checked October 29, 2026)

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.